Head-To-Head Survey: Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) & H-CYTE (OTCMKTS:HCYTD)

Volatility and Risk

H-CYTE has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Defiance Daily Target 2X Long LMND ETF has a beta of 9.29, suggesting that its share price is 829% more volatile than the S&P 500.

Insider and Institutional Ownership

87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. 5.2% of H-CYTE shares are owned by company insiders. Comparatively, 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares H-CYTE and Defiance Daily Target 2X Long LMND ETF”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A
Defiance Daily Target 2X Long LMND ETF	$437.66 million	0.01	$15.17 million	$0.51	32.53

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than H-CYTE.

Profitability

This table compares H-CYTE and Defiance Daily Target 2X Long LMND ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
H-CYTE	-450.40%	N/A	-777.68%
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%

Summary

Defiance Daily Target 2X Long LMND ETF beats H-CYTE on 8 of the 9 factors compared between the two stocks.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

About Defiance Daily Target 2X Long LMND ETF

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.